Evidence map›Paper›PMID 42171009›Full record

ArticleOtolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery2026

Rates and Outcomes of Head and Neck Cancer Among Patients With Primary Immunodeficiency Disorders.

Talia A Wenger, Casey Collet, Jonathan West, Uttam K Sinha

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Talia A WengerKeck School of Medicine of the University of Southern California, Department of Otolaryngology-Head & Neck Surgery, Los Angeles, California, USA.ORCID https://orcid.org/0000-0001-6616-2780
Casey ColletKeck School of Medicine of the University of Southern California, Department of Otolaryngology-Head & Neck Surgery, Los Angeles, California, USA.
Jonathan WestKeck School of Medicine of the University of Southern California, Department of Otolaryngology-Head & Neck Surgery, Los Angeles, California, USA.
Uttam K SinhaKeck School of Medicine of the University of Southern California, Department of Otolaryngology-Head & Neck Surgery, Los Angeles, California, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivePatients with primary immunodeficiency disorders (PID) have increased hematological cancer risk but the risk of head and neck cancer (HNC) is not well-established. Here, we sought to compare the risk of HNC among patients with PID to that of the general population. Furthermore, we report overall outcomes among HNC patients with and without PID. STUDY

designRetrospective cohort study.

settingTriNetX, a database containing millions of deidentified health records, and Surveillance, Epidemiology, and End Results (SEER) 2017 to 2021.

methodsA comparative analysis of HNC incidence among patients with PID versus the general population. Outcomes analyses were conducted on 1:1 propensity matched cohorts of patients with HNC with and without PID.

resultsPatients with PID had a significantly increased risk of HNC compared to the general population with an overall SIR (95% CI) of 6.55 (5.13-8.13) for oral cavity and pharynx cancer. Among patients with HNC, those with PID had a significantly increased risk of mortality (HR 1.39, 95% CI 1.17-1.66) and malnutrition (OR 1.34, 95% CI 1.21-1.49).

conclusionPatients with PID have significantly increased incidence of HNC compared to the general population. Moreover, HNC patients with PID face an increased risk of post-operative complications and mortality.

Indexed as

Head and Neck NeoplasmsPrimary Immunodeficiency DiseasesAdultFemaleHumansIncidenceMaleMiddle AgedRetrospective StudiesSEER Programcommon variable immunodeficiencyhead and neck squamous cell carcinomaIgA deficiencysevere combined immunodeficiencyX‐linked agammaglobulinemia

Identifiers

PMID42171009
PMCPMC13525896

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.